Pavella Therapeutics Inc. Intrinsic Value

PVLA

Pavella Therapeutics fair value

None of the figures this calculator works from (earnings, free cash flow, revenue, book value, dividends) is positive for Pavella Therapeutics today, so there is nothing to project yet.

SourceFair value computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 5 Aug 2026. How this is calculated.

Price from market data, last close as of 4 Nov 2026. Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PVLA

CompareIntrinsic value

ARWRArrowhead Pharmaceuticals Inc.

$61.65+3.56%40

TVTXTravere Therapeutics Inc.

$52.64+6.54%52

RIGLRigel Pharmaceuticals, Inc.

$51.29+4.97%87

SNDXSyndax Pharmaceuticals Inc.

$10.45-26.87%0

INDVIndivior Pharmaceuticals, Inc.

$36.28+2.57%80

JAZZJazz Pharmaceuticals plc

$234.66+2.14%58

OCULOcular Therapeutix Inc.

$7.14+4.69%10

ABBVAbbVie Inc.

$294.83+3.09%49

Held by ETFs

PVLA is in 29 US ETFs. The largest of them, with PVLA's weight in each:

Spot a number that looks wrong? Check it in PVLA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PVLA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.